Timing of intravenous immunoglobulin treatment and outcome in Guillain–Barré syndrome: Is time nerve?

Introduction/Aims Methods Results Discussion Despite treatment, a considerable proportion of patients with Guillain–Barré syndrome (GBS) experience poor recovery, highlighting a therapeutic need. There is a lack of evidence that treatment timing affects recovery. This study aims to investigate the effects of intravenous immunoglobulin (IVIg) timing on disability and speed of recovery in GBS.We performed a retrospective study of 136 IVIg‐treated GBS patients admitted to two Korean centers between 2010 and 2021. We analyzed the effect of time to IVIg on the GBS disability scale (GBS‐DS) and the degree of improvement from nadir (∆GBS‐DS) at 1, 3, 6, and 12 months, as well as the time to regain the ability to walk or run unaided. Time to IVIg was treated either as a continuous variable or categorized into 1‐week intervals to explore critical time windows. Known prognostic factors, the modified Erasmus GBS Outcome Scores on admission and pre‐treatment serum albumin levels were adjusted as covariates.Shorter time to IVIg was independently associated with better GBS‐DS, greater ∆GBS‐DS, and shorter time to walk or run unaided at all time points. The therapeutic effect of IVIg was notably diminished when administered beyond the first 2 weeks of onset.Our study highlights the timing of IVIg as a modifiable prognostic factor in GBS. The earlier IVIg is initiated, the better the outcomes, with the ideal time window being within the first 2 weeks. These findings underscore the importance of prompt diagnosis and early intervention to optimize recovery in GBS patients. [ABSTRACT FROM AUTHOR]